FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*]	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Konidaris Tasos (Last) (First) (Middle)	**Amneal Pharmaceuticals, Inc. [AMRX]**	_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) **Executive Vice President & CFO**
C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD (Street)	3. Date of Earliest Transaction (MM/DD/YYYY) **3/3/2026**	
BRIDGEWATER, NJ 08807 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Common Stock	**3/3/2026**		**M**		**45,290** [(1)]	**A**	[(2)]	**167,442**	**D**	
Class A Common Stock	**3/3/2026**		**F**		**16,182** [(3)]	**D**	**$13.31**	**151,260**	**D**	
Class A Common Stock	**3/3/2026**		**M**		**57,339** [(1)]	**A**	[(2)]	**208,599**	**D**	
Class A Common Stock	**3/3/2026**		**F**		**24,251** [(3)]	**D**	**$13.31**	**184,348**	**D**	
Class A Common Stock	**3/3/2026**		**M**		**28,538** [(1)]	**A**	[(2)]	**212,886**	**D**	
Class A Common Stock	**3/3/2026**		**F**		**14,298** [(3)]	**D**	**$13.31**	**198,588**	**D**	
Class A Common Stock	**3/3/2026**		**M**		**458,716**	**A**	[(4)]	**657,304**	**D**	
Class A Common Stock	**3/3/2026**		**F**		**229,817** [(5)]	**D**	**$13.31**	**427,487**	**D**	
Class A Common Stock	**3/4/2026**		**M**		**43,982** [(1)]	**A**	[(2)]	**471,469**	**D**	
Class A Common Stock	**3/4/2026**		**F**		**22,035** [(3)]	**D**	**$13.3**	**449,434**	**D**	

Table II - Derivative Securities Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	[(2)]	**3/3/2026**		**M**			**45,290**	[(6)]	[(6)]	**Class A Common Stock**	**45,290**	**$0**	**0**	**D**	
Restricted Stock Units	[(2)]	**3/3/2026**		**M**			**57,339**	[(7)]	[(7)]	**Class A Common Stock**	**57,339**	**$0**	**57,340**	**D**	
Restricted Stock Units	[(2)]	**3/3/2026**		**M**			**28,538**	[(8)]	[(8)]	**Class A Common Stock**	**28,538**	**$0**	**85,617**	**D**	
Performance-Based Restricted Stock Units	[(4)]	**3/3/2026**		**M**			**458,716**	[(4)]	[(4)]	**Class A Common Stock**	**458,716**	**$0**	**0**	**D**	
Restricted Stock Units	[(2)]	**3/4/2026**		**M**			**49,982**	[(9)]	[(9)]	**Class A Common Stock**	**49,982**	**$0**	**87,963**	**D**	

Table II - Derivative Securities Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

(1) Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

(2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

(3) Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

(4) Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

(5) Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.

(6) On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

(7) On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

(8) On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

(9) On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Konidaris Tasos **C/O AMNEAL PHARMACEUTICALS, INC.** **400 CROSSING BOULEVARD** **BRIDGEWATER, NJ 08807**			**Executive Vice President & CFO**	

Signatures

/s/ Denis Butkovic, Attorney-in-Fact	**3/5/2026**
**Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.